CAH · Analysis updated Nov 5, 2026, 10:36 AM ET

Why is Cardinal Health, Inc. (CAH) stock moving?

Cardinal Health's fiscal first-quarter revenue rose 5% to $67.5 billion, about $1 billion above estimates, and adjusted earnings rose 28% to $3.26 a share, well above the roughly $2.94 expected. Profit in its main pharmaceutical unit rose 17% on brand-name and specialty drugs. It raised its full-year adjusted EPS outlook to $12.80-13.00 from $12.40-12.60 (analysts expected about $12.56) and lifted its pharma profit-growth target to 10-12%. It also signed a binding letter of intent to renew its drug-distribution contracts with CVS Health. At about 10:27 AM ET the stock was $277.80, up 6.1%, after touching a record $286.29.

News behind the analysis

Cardinal Health Reports First Quarter Fiscal Year 2027 Results and Raises Outlook
PR Newswire (company release) · Nov 4, 2026
Revenue $67.5B (+5%); adjusted EPS $3.26 (+28%); FY27 adjusted EPS outlook raised to $12.80-13.00; $500M buyback completed; CVS letter of intent.
Cardinal Health Q1 2027: EPS beats by 11%, CVS deal secured
24/7 Wall St. · Nov 4, 2026
EPS $3.26 vs $2.94 consensus; fourth straight beat; CVS renewal removes the biggest customer-concentration question.
Cardinal Health beats estimates, raises guidance
Investing.com · Nov 4, 2026
Revenue beat the $66.59B estimate; guidance midpoint $12.90 vs $12.56 consensus.
Cardinal Health Q1 2027 Earnings Call Transcript
Benzinga · Nov 4, 2026
Pharma profit growth target raised to 10-12%; earnings growth to moderate in Q2 and Q3 before strengthening in Q4.

In the Daily Standout

November 5, 2026: on the shortlist +6.06%

For informational and educational purposes only. Not investment advice. Prices are an intraday snapshot (about 10:27 AM ET) and move quickly; sentiment and confidence scores are model opinions, not guarantees. Do your own research.